Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of TSPO PET Radioligands with Emapunil Blocking
NCT02181582Phase 1Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of (R)-[11C]PK11195, [11C]DPA-713 and [11C]ER176 in multiple sclerosis (MS), herpes simplex encephalitis (HSE), Parkinson's disease (PD) and 2 more (3 arms), sponsored by National Institute of Mental Health. Primary endpoint: Signal noise ratio [C-11](R)-PK 11195 at 2 months. Started Jun 2014; status: completed.
02
Drugs
(R)-[11C]PK11195[11C]DPA-713[11C]ER176
03
Conditions
multiple sclerosis (MS)herpes simplex encephalitis (HSE)Parkinson's disease (PD)Alzheimer's disease (AD)ischemic stroke
Beyond the preview
Go deeper on NCT02181582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181582.